CERE Insider Trading
Notice: This stock is marked as potentially delisted. It may not be actively trading.
Insider Ownership Percentage: 5.10%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $3,134,500.00
Cerevel Therapeutics Insider Trading History Chart
This chart shows the insider buying and selling history at Cerevel Therapeutics by year and by quarter.
Skip ChartChart Data in Insider Trading History Table
Cerevel Therapeutics Share Price & Price History
Current Price: $44.96
Price Change: +0.30 (1.20%)
As of 08/1/2024 01:00 AM ET
Cerevel Therapeutics Insider Trading History
Cerevel Therapeutics Institutional Trading History
Data available starting January 2016
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; and CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and PDE4 inhibitor for the treatment of psychiatric, neuroinflammatory, and other disorders. Cerevel Therapeutics Holdings, Inc. was founded in 2018 and is headquartered in Cambridge, Massachusetts.
Read More on Cerevel Therapeutics
Today's Range
Now: $44.96
52 Week Range
Now: $44.96
Volume
N/A
Average Volume
1,709,788 shs
Market Capitalization
$8.19 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.4
Who are the company insiders with the largest holdings of Cerevel Therapeutics?
Cerevel Therapeutics' top insider investors include:
- Bain Capital Investors Llc (Major Shareholder)
- Perceptive Advisors Llc (Director)
- Marijn E Dekkers (Director)
- Ronald C Renaud Jr (CEO)
- N Anthony Coles (Director)
- Kenneth Dipietro (Insider)
- Paul D Burgess (Insider)
- Mark Bodenrader (Insider)
- Susan Altschuller (CFO)
- Ramiro Sanchez (Insider)
- John Renger (Insider)
- N Anthony Coles (CEO)
- Scott Akamine (Insider)
Learn More about top insider investors at Cerevel Therapeutics.